Investigational Drugs for the Treatment of Postherpetic Neuralgia: Systematic Review of Randomized Controlled Trials.
AAK1
AT2R
COX
LANCL
NMDA
analgesic
first in class
nerve growth factor
neuropathic pain
opioid
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
20 Aug 2023
20 Aug 2023
Historique:
received:
25
07
2023
revised:
17
08
2023
accepted:
18
08
2023
medline:
28
8
2023
pubmed:
26
8
2023
entrez:
26
8
2023
Statut:
epublish
Résumé
The pharmacological treatment of postherpetic neuralgia (PHN) is unsatisfactory, and there is a clinical need for new approaches. Several drugs under advanced clinical development are addressed in this review. A systematic literature search was conducted in three electronic databases (Medline, Web of Science, Scopus) and in the ClinicalTrials.gov register from 1 January 2016 to 1 June 2023 to identify Phase II, III and IV clinical trials evaluating drugs for the treatment of PHN. A total of 18 clinical trials were selected evaluating 15 molecules with pharmacological actions on nine different molecular targets: Angiotensin Type 2 Receptor (AT2R) antagonism (olodanrigan), Voltage-Gated Calcium Channel (VGCC) α2δ subunit inhibition (crisugabalin, mirogabalin and pregabalin), Voltage-Gated Sodium Channel (VGSC) blockade (funapide and lidocaine), Cyclooxygenase-1 (COX-1) inhibition (TRK-700), Adaptor-Associated Kinase 1 (AAK1) inhibition (LX9211), Lanthionine Synthetase C-Like Protein (LANCL) activation (LAT8881), N-Methyl-D-Aspartate (NMDA) receptor antagonism (esketamine), mu opioid receptor agonism (tramadol, oxycodone and hydromorphone) and Nerve Growth Factor (NGF) inhibition (fulranumab). In brief, there are several drugs in advanced clinical development for treating PHN with some of them reporting promising results. AT2R antagonism, AAK1 inhibition, LANCL activation and NGF inhibition are considered first-in-class analgesics. Hopefully, these trials will result in a better clinical management of PHN.
Identifiants
pubmed: 37629168
pii: ijms241612987
doi: 10.3390/ijms241612987
pmc: PMC10455720
pii:
doi:
Substances chimiques
Drugs, Investigational
0
Nerve Growth Factor
9061-61-4
Pregabalin
55JG375S6M
Types de publication
Journal Article
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Spanish Ministry of Economy and Competitiveness (MINECO)
ID : FPU21/02736
Références
Ann Clin Lab Sci. 2015 Summer;45(4):426-32
pubmed: 26275694
J Multidiscip Healthc. 2016 Sep 21;9:447-454
pubmed: 27703368
Mol Pain. 2022 Apr;18:17448069221107781
pubmed: 35647699
Mar Drugs. 2023 May 21;21(5):
pubmed: 37233510
Proc Natl Acad Sci U S A. 2013 Feb 26;110(9):3603-8
pubmed: 23401543
Clin Transl Immunology. 2023 Mar 23;12(3):e1443
pubmed: 36969366
Cochrane Database Syst Rev. 2015 Jun 02;(6):CD003348
pubmed: 26035341
Sci Rep. 2021 Oct 6;11(1):19827
pubmed: 34615968
Pain. 2021 Oct 1;162(10):2578-2589
pubmed: 33675631
Curr Opin Pharmacol. 2006 Feb;6(1):108-13
pubmed: 16376147
Dev Cell. 2014 Aug 25;30(4):479-87
pubmed: 25158856
J Pain Res. 2020 May 26;13:1223-1241
pubmed: 32547184
Genome Biol. 2003;4(3):207
pubmed: 12620097
Clin Drug Investig. 2022 May;42(5):403-416
pubmed: 35435639
Pain. 2003 Jul;104(1-2):15-23
pubmed: 12855310
Clin J Pain. 2018 Nov;34(11):1025-1031
pubmed: 29698250
Pain. 2011 Mar;152(3):649-655
pubmed: 21239111
Pain. 1996 Oct;67(2-3):241-51
pubmed: 8951917
Mar Drugs. 2018 Jun 05;16(6):
pubmed: 29874779
Mayo Clin Proc. 2009 Mar;84(3):274-80
pubmed: 19252116
Pharmaceuticals (Basel). 2022 Jul 03;15(7):
pubmed: 35890126
J Pain Res. 2019 Aug 20;12:2537-2545
pubmed: 31686896
Pain Pract. 2017 Jan;17(1):62-69
pubmed: 26714731
Pain Ther. 2023 Feb;12(1):1-18
pubmed: 36334235
BMJ. 2021 Mar 29;372:n71
pubmed: 33782057
J Clin Anesth. 2015 Jun;27(4):296-300
pubmed: 25792176
Diabetes Care. 2014 Dec;37(12):3253-61
pubmed: 25231896
World J Clin Cases. 2022 May 6;10(13):4220-4225
pubmed: 35665100
Int J Neuropsychopharmacol. 2019 Oct 1;22(10):616-630
pubmed: 31290965
Neuropharmacology. 2017 Feb;113(Pt A):217-230
pubmed: 27743933
Clin J Pain. 2017 Feb;33(2):99-108
pubmed: 27153360
Nat Rev Rheumatol. 2021 Jan;17(1):34-46
pubmed: 33219344
J Pain Res. 2017 Feb 20;10:439-443
pubmed: 28255254
Int J Clin Pharm. 2023 Jun;45(3):556-565
pubmed: 36848024
Postgrad Med. 2013 Jul;125(4):191-202
pubmed: 23933906
J Manag Care Pharm. 2012 Sep;18(7):527-39
pubmed: 22971206
Neurology. 1998 Jun;50(6):1837-41
pubmed: 9633737
Front Pharmacol. 2020 Dec 23;11:571994
pubmed: 33424587
Drugs Aging. 2012 Nov;29(11):863-9
pubmed: 23038608
Anesthesiology. 2003 Nov;99(5):1175-9
pubmed: 14576556
Neural Plast. 2022 Apr 25;2022:9762244
pubmed: 35510269
Medicine (Baltimore). 2020 Sep 4;99(36):e21976
pubmed: 32899037
Clin Infect Dis. 2021 Nov 2;73(9):e3210-e3217
pubmed: 32829399
Expert Rev Neurother. 2007 Nov;7(11):1581-95
pubmed: 17997705
Pain Manag. 2017 Jul;7(4):255-267
pubmed: 28415907
Clin J Pain. 2018 May;34(5):450-467
pubmed: 28877137
Cell. 2021 May 13;184(10):2680-2695.e26
pubmed: 33932340
Neuron. 2023 Jun 15;:
pubmed: 37352856
Cochrane Database Syst Rev. 2007 Apr 18;(2):CD004846
pubmed: 17443559
Expert Opin Pharmacother. 2016;17(4):601-9
pubmed: 26809783
J Pharmacol Exp Ther. 2016 Sep;358(3):371-86
pubmed: 27411717
J Neurochem. 2005 Aug;94(4):1131-9
pubmed: 16092950
Pain. 2019 May;160(5):1175-1185
pubmed: 30913164
Br J Clin Pharmacol. 2014 Feb;77(2):357-67
pubmed: 23432384
Cell Death Differ. 2020 Apr;27(4):1369-1382
pubmed: 31570855
Expert Rev Clin Pharmacol. 2011 May;4(3):379-88
pubmed: 21686074
Value Health. 2008 Jan-Feb;11(1):44-7
pubmed: 18237359
Curr Med Chem. 2010;17(32):3769-805
pubmed: 20858219
Lancet. 2014 May 10;383(9929):1637-1647
pubmed: 24507377
Clin J Pain. 2017 Apr;33(4):310-318
pubmed: 28266963
Korean J Pain. 2021 Apr 01;34(2):210-216
pubmed: 33785673
Pharmacol Rev. 2013 Sep 27;65(4):1257-317
pubmed: 24076545
Pharmaceuticals (Basel). 2021 Jan 31;14(2):
pubmed: 33572689
Eur Neuropsychopharmacol. 2006 Jul;16 Suppl 2:S128-33
pubmed: 16765030
Clin Ther. 2021 May;43(5):822-835.e16
pubmed: 34059327
Arthritis Rheumatol. 2016 Feb;68(2):382-91
pubmed: 26554876
Pain Med. 2010 Nov;11(11):1726-42
pubmed: 21044263
Patient Prefer Adherence. 2013 May 20;7:419-34
pubmed: 23737662
Pain Rep. 2021 Mar 09;6(1):e869
pubmed: 33981922
Clin Pharmacol Ther. 2017 Oct;102(4):611-622
pubmed: 28710775
Clin J Pain. 2017 Jul;33(7):569-578
pubmed: 27753650
Inflamm Bowel Dis. 2020 Mar 4;26(4):643-652
pubmed: 31077582
Can J Anaesth. 2019 Jul;66(7):820-827
pubmed: 31098961
Pharmaceutics. 2021 Mar 26;13(4):
pubmed: 33810493
Pain Med. 2013 May;14(5):692-705
pubmed: 23489258
Clin Ther. 2021 Jun;43(6):1029-1050
pubmed: 34108079
J Pharmacol Exp Ther. 2021 Mar;376(3):330-337
pubmed: 33293377
Eur J Pharmacol. 2001 Oct 19;429(1-3):71-8
pubmed: 11698028
Curr Drug Targets. 2014 Jun;15(6):565-72
pubmed: 24628287
J Med Chem. 2022 Mar 24;65(6):4457-4480
pubmed: 35257579
N Engl J Med. 2014 Oct 16;371(16):1526-33
pubmed: 25317872
Pain Pract. 2023 Mar;23(3):277-289
pubmed: 36478501
Curr Pain Headache Rep. 2016 Mar;20(3):17
pubmed: 26879875
Clin J Pain. 2022 Feb 28;38(5):343-350
pubmed: 35220330
Drugs. 2019 Mar;79(4):463-468
pubmed: 30778848
J Pain Res. 2015 Feb 13;8:87-94
pubmed: 25709497
Expert Opin Pharmacother. 2017 Nov;18(16):1739-1750
pubmed: 29025327
Int J Pharm. 2018 Oct 25;550(1-2):160-169
pubmed: 30138708